A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Completed · Phase 4

Conditions studied: Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection

In brief

The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).

Key facts

Study ID
NCT00067730
Run by
Eli Lilly and Company
People needed
7
Starts
2003-03-01
Expected to finish
2003-10-01
Last updated by the study team
2007-12-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.